NanoThea

NanoThea is able to achieve this by closing well known radioisotopes in our polysaccharide nanoparticles and targeting system. NanoThea is developing an innovative radiopharmaceutical for PET diagnosis and treatment of patients with metastatic tumors that are resistant to current used therapies. NanoThea will use a molecule that can bind with various types of radioisotopes/elements using our nanoparticle for different diagnostic methods: e.g. Now we are working to go global with our idea. The aim of the company is to create products capable of higher precision and less side effects in cancer imaging and radiotherapy. The unique features of our product are: – the nanoparticles’ structure allows high tumor/blood ratio, increasing safety of the radiotherapy – appropriate engineered linker for targeting molecule – radiochemical stability – lack of toxicity of the carrier – materials approved by FDA for safety (dextran) – radiolabeling in situ in the hospital, before administration. The innovative approach to the radioisotope carrier focuses on maximizing availability of nanoparticles for cancer cells spread within the organism. To maximize the efficiency our products are characterized with higher tumor/blood ratio when compared to current solutions which increases safety and efficacy of solution.